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A B S T R A C T
Nerve growth factors and their receptors have received an increasing attention in certain cancers since
they play an important role in regulating tumorigenesis, biological process and metastasis. Here we aimed
at characterizing a new function of one of the subtypes of growth factor receptors (GFR), GFRα2, in pan-
creatic cancer. In this study, we showed that GFRα2 was up-regulated in pancreatic adenocarcinoma and
was positively correlated with tumor size and perineural invasion, which indicated that it may be as-
sociated with cell growth and apoptosis. Mechanically, we discovered that high GFRα2 expression level
leads to PTEN inactivation via enhancing Mir-17-5p level.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Currently, pancreatic adenocarcinoma (PDAC) is one of the most
aggressive human malignancies. Due to the lack of early symp-
toms, most of the patients are diagnosed at late stage; thus, the
average survival time is usually less than 6 months and the 5-year
survival rate hovers around 5% [1,2]. Even for those patients who
received radical resection, they still suffer from the problem of re-
currence [3]. Chemoresistance is a major barrier for treating PDAC,
which can arise de novo or requires refractoriness. Gemcitabine has
been recognized as the ﬁrst-line drug to treat PDAC for a long time;
however, insensitivity due to singleness of therapeutic target is the
major concern during its clinical application [4]. Hence, investigat-
ing the molecular mechanism of chemoresistance is becoming a real
challenge.
Growth factor receptor α (GFRα) contains four members – GFRα1,
GFRα2, GFRα3 and GFRα4 – cooperatingwith transmembrane receptor
tyrosine kinase RET, which receives signal from glial cell line-
derived factor (GDNF) family [5]. These structures are crucial for
normal development of kidney and nerves [6,7]. GFRα2 is a common
receptor for both GDNF and neurturin. Besides the role of main-
taining endocrine homeostasis in pituitary [8], it has been reported
to be correlated with neuropathic pain [9] and neuronal plasticity
[10]. However, its speciﬁc function in cancer is still not clear.
Mir-17-5p belongs to Mir-17-92 cluster [11], which is involved
in a wide range of biological functions and processes such as de-
velopment, energymetabolism, immune response, cell differentiation
and carcinogenesis [12,13]. Previous studies indicated that Mir-17-
5p was often up-regulated in various cancers and functions as an
oncogenicMirRNA [14–16]. Phosphatase and tensinhomologdeleted
on chromosome 10 (PTEN) gene is a tumor suppressor gene that
acts a pivotal role in cell growth, development, signal transduction
andapoptosis [17,18]. PTEN inactivation leads tomany types of cancer
including PDAC [18].Mass spectrometry analysis showed that GFRα2
interacts with PTEN [19], which may offer a new way to clarify the
downstream mechanism of GFRα2 to inﬂuence biological process
of cancer. The Mir-17-5p/PTEN axis has been reported to be highly
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related to chemoresistance in certain cancer such as ovarian cancer
andprostate cancer [16,20].However, the speciﬁc correlationbetween
GFRα2 and PTEN and whether the chemoresistant axis of Mir-17-
5p/PTEN exists in PDAC are still unknown.
This study shows that GFRα2 may enhance cell survival by re-
pressing the expression level of PTEN via recruiting Mir-17-5p, and
GFRα2/Mir-17-5p/PTEN could enhance cell survival and chemore-
sistance in PDAC. Thus, inhibiting this pathway may be a potential
target in PDAC therapy.
Materials and methods
Patients and tissue collection
58 pairs of PDAC samples and two normal pancreases were collected from pa-
tients who underwent surgical resection at the Department of General Surgery of
Ruijin Hospital between 2008 and 2010 and were well-documented with clinical
information. Surgical specimens were conﬁrmed by pathological examination and
all of the patients did not receive any anti-tumor treatment like chemotherapy or
radiotherapy before surgery. Tumor staging was determined by the latest edition
of the TNM system of the American Joint Committee. The project was approved by
the Ethics Committee of Ruijin Hospital aﬃliated to Shanghai Jiao Tong University
and all subjects signed an informed consent form. Details about the patients’ in-
formation will not be disclosed.
Immunochemistry analysis
All samples were ﬁxed in 4% paraformaldehyde (pH 7.4) overnight at 4 °C and
then dehydrated in different concentrations of ethanol. Immunochemistry stain-
ing and analytical methodswere performed according to our group’s previousmethods
[21]. Anti-GFRα2 (Proteintech, #21973-1-AP) and anti-PTEN (Cell Signaling Tech-
nology, #9188) were used in the experiments.
Cell culture and reagents
PanC-1, Mia Paca-2 and HEK-293T were purchased from ATCC and were au-
thenticated by DNA typing at the Shanghai Jiao Tong University Analysis Core. Cells
were cultured in DMEM medium (HyClone) with 10% FBS (Life Technologies),
0.1 mmol/ml sodium pyruvate (Gibco), penicillin [50 U/ml]/streptomycin [50 μg/ml]
(Gibco) at 37 °C under 5% CO2 in a humidiﬁed chamber.
Plasmid construction
Lenti-virus vector pGMLV-PD1 (without ﬂuorescence) was digested by restric-
tion endonuclease (NEB) between BamHI and EcoRI; full-length cDNA of GFRα2 and
PTEN were cloned from PanC-1 and then ligated by ClonExpress II One Step Cloning
Kit (Vazyme Biotech Co., Ltd, #C112-02). The shRNA targeted GFRα2, purchased from
Sigma, was inserted into pLKO.1 vector. Empty vectors were used as negative control.
Virus packing and infection
Lenti-virus plasmids were transfected into HEK-293T with virus packing plas-
mids by Lipo2000 (Invitrogen) to produce lenti-virus. The culture supernatants were
collected at 48 h and 72 h and added to pancreatic cancer cell lines to construct stable
cell lines via puromycin selection.
Luciferase report assay
Plasmids containing wild-type Luc-PTEN (WT) andmutant Luc-PTEN 3’UTR were
specially synthesized. Mir-17-5p mimics were synthesized by Biotend (Shanghai,
China). Luciferase activities of the indicated cells were measured using the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI) 60 h after transfection
according to the manufacturer’s instruction. Activities were normalized to Renilla
luciferase.
Western blot analysis
Cells were lysed with pre-chilled lysis buffer (Beyotime, #P0013) and total pro-
teins were qualiﬁed by BCA assay (Beyotime, #P0012). Then western blot assay was
performed as described previously [21]. Antibodies were the same as IHC staining.
GAPDH was used as internal control (Abcam). The western blot images were cap-
tured by a Tanon-5200 Chemiluminescent Imaging System (Tanon, China, Shanghai).
RNA isolation and qPCR analysis
Total RNA were isolated by TRIzol (Invitrogen) according to the manufacturer’s
protocol. The quality and concentration of RNA were evaluated by a spectropho-
tometer. 1 μg of total RNA was used for ﬁrst-strand synthesis (TIANGEN Biotech
(Beijing) Co., Ltd). Real-time PCRwas performed by the SYBR Green PCRmethod using
the All-in-One miRNA qPCR Detection Kit (GeneCopoeia, Rock, MD, USA) in tripli-
cate. The following forward primers were purchased from GeneCopoeia: has-Mir-
17-5p, 5′-ACTACCTGCACTGTAAGCACTTTG-3′; small nuclear RNA(U6): 5′-
CAAATTCGTGAAGCGTTCCATAT-3′. For mRNA detection, 1 μg of total RNA was
used for cDNA synthesized by HiScript II 1st Strand cDNA synthesis Kit (Vazyme Bio
Co., Ltd, #R211-02). Real-time PCR was performed in triplicate using SYBR Green
Mix (Roche). The primers for targeted genes are as follows. GFRA2: 5′-
CCGACTTCCATGCCAATTGT-3′ (Forward) and 5′-ATGTCAAACCCAATCATGCCA-3′
(Reverse), PTEN: 5′-GCTACCTGTTAAAGAATCATCTGG-3′ (Forward) and 5′-
CATGAACTTGTCTTCCCGT-3′ (Reverse), GAPDH: 5′-CACCATGAAGATCAAGATCATTGC-
3′ (Forward) and 5′-GGCCGGACTCATCGTACTCCTGC-3′ (Reverse).
The U6 and GAPDH were used as internal controls for MirRNA and mRNA re-
spectively. The threshold cycle (Ct) values were analyzed.
Colony formation assay and cell growth counting
For colony formation assay, 500 cells were plated into a 6-well plate. After 2 weeks
of regular culture, cells were washed with PBS and then ﬁxed with methanol for
15 min before staining with 1% Giemsa for 15 min and washed 3 times with PBS.
For cell counting assay, cells were plated in a 96-well plate at a density of 2 × 103
cells. Every two days one set of cultures was tested followed by TransDetect cell count-
ing kit (CCK-8, TransGen Biotech) at 450 nm.
Coimmunoprecipitation (Co-IP) assay
Co-IP assay was performed according to our previous protocol [22]. Brieﬂy, cells
were lysed in pre-chilled lysis buffer (Beyotime #P0013) with protease inhibitor cock-
tail (Roche). Protein A beads were incubated with anti-PTEN antibody (Cell Signaling
Technology, #9188) for 4 h and then incubated with total protein lysis overnight.
Then the precipitated protein was used for western blot analysis as the previous
method.
Study approval
This study was approved by the Ethics and Research Committees of Ruijin Hos-
pital, Shanghai Jiao Tong University, School of Medicine and conducted in accordance
with the Declaration of Helsinki Principles. The procedures for pancreatic tumor re-
sectionwere described in detail to all patients before admission, and informed consent
was obtained for all participating patients.
Results
GFRα2 is up-regulated in PDAC and positively correlated with tumor
size and poorer prognosis
The protein expression level of GFRα2wasmeasured in 58 tumor
samples and their corresponding peri-tumor tissues by IHC. GFRα2
expression was nearly negative in the two normal pancreatic tissues
(Fig. 1A), while signiﬁcant differences were found between tumor
and peri-tumor tissues (Fig. 1B and C). The association between gene
expression and other clinical parameters was shown in Table 1, in-
dicating that patients with higher GFRα2 expression had a larger
tumor size and higher rate of perineural invasion compared with
those with lower GFRα2 level. In addition, the GFR α2 expression
level was correlated with poorer prognosis (Fig. 1D). These results
implicated that GFRα2 may play a role in cell survival rate, espe-
cially growth and apoptotic ability.
GFRa2 could enhance progression of PDAC cells and down-regulate
PTEN expression
To further investigate the function of GFRα2 in pancreatic cancer,
we constructed stable GFRα2 over-expression (pGMLV-PD1) and
knock-down (pLKO.1) cell lines using twopancreatic cancer cell lines:
PanC-1 and Mia Paca-2. Colony formation assay and cell prolifer-
ation rate assay were carried out in control and over-expression
groups. It was clearly shown that both the colony formation and
the proliferation abilitieswere signiﬁcantly enhanced inGFRα2over-
expression (GFRα2 OE) group (Fig. 2A–C). We also injected the two
group cell lines into nude mice to study subcutaneous tumor for-
mation. As expected, over-expression of GFRα2 resulted in increased
tumor growth in vivo (Fig. 2D). At the same time, we used shRNA to
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knock down the expression level of GFRα2 (Fig. 2E). We found that
knock-downof GFRα2 in pancreatic cancer cells attenuated cell pro-
liferation and colony formation (Fig. 2F and G). Further, we checked
the expression level of PTEN inGFRα2OE and control cells of PanC-1
andMia Paca-2. The results showed that PTENpresented lower level
in the GFRα2 OE group (Figs. 2H and 3G). These ﬁndings suggested
that GFRα2 could prompt tumor growth and repress PTEN expres-
sion level. In order to validate the capacity of GFRα2 in promoting
cell growth in vivo, we also detected the Ki-67 index in the xeno-
grafts (Supplementary Fig. S1A and B) and the result showed that
the index was much higher in the GFRa2 OE group.
Mir-17-5p was up-regulated by GFRα2 and directly targeted to PTEN
According to one study published in 2015 [23], we askedwhether
the correlation betweenMir-17-5p and GFRα2 also existed in PDAC.
We checked the Mir-17-5p level in Mia Paca-2 cells, which express
low levels of endogenousMir-17-5p, before and after over-expressing
GFRα2. The results showed that Mir-15-5p was signiﬁcantly up-
regulated in the GFRα2 OE group (Fig. 3A). Since MirRNAs are often
involved in regulatory feedback pathways, we wanted to know
whether Mir-17-5p was also the case. Indeed, by using the MirRNA
database TargetScan, we identiﬁed PTEN mRNA as one of the pu-
tative Mir-17-5p targets. To validate this prediction, we treated Mia
Paca-2 cells with Mir-17-5p mimics and control MirRNA, and de-
tected the PTEN expression level with qRT-PCR (data not shown)
and western blot assay (Fig. 3B). In line with these results, we iden-
tiﬁed the binding sites of Mir-17-5p in PTEN 3′UTR by luciferase
report assay (Fig. 3C and D). Taken together, we indicated that PTEN
was directly regulated by Mir-17-5p and this MicroRNA was the
bridge between GFRα2 and PTEN. In order to validate the regula-
tion relationship clearly, we ﬁrst used Co-IP assay to detect whether
GFRα2 could interact with PTEN directly as the previous mass spec-
trometry indicate [19]; however, this direct interaction seemed not
to exist in pancreatic cancer cell line (Fig. 3E). Next, we compared
PTEN level and cell proliferation rate by CCK-8 after over-expressing
GFRα2 with or without Mir-17-5p mimics and inhibitor (Fig. 3F).
These results demonstrated that GFRa2 could not interact with PTEN
directly and Mir-17-5p acted a role as a “bridge” to combine GFRα2
and PTEN. Because in GFRa2 OE cells ectopic expression of Mir-17-
5p could further decrease the PTEN level and promote cell
proliferation, inhibiting it could have the opposite effects (Fig. 3G
and Supplementary Fig. S1C, D).
Mir-17-5p expression level was up-regulated in PDAC and positively
correlated with GFRα2 expression level in PDAC samples
Based on the previous ﬁndings, we assessed whether Mir -17-
5p was up-regulated in PDAC. MicroRNAs were extracted from the
previous tissues and qRT-PCR was used to detect Mir-17-5p ex-
pression level. Scatter diagramwas shown to indicate that expression
of Mir-17-5p in tumor tissues was much higher than that in
Fig. 1. Immunohistochemistry test of GFRα2 in PDAC tissues and peri-tumor tissues. (A) GFRα2 was nearly negative in two totally normal pancreatic tissues except some
weakly positive in islet regions. Black triangle showed the positive cells. (B) Different expression levels in paired tumor and peri-tumor tissues. Notice that in patient 1 the
difference is not as obvious as that in patient 2. The arrow showed the positive cells. (C) Chi-square test of the 58 patients of paired tissues. Each group was shown by dis-
tribution of IHC staining scores. Only scores ≥4 were considered high. (D) Kaplan–Meier analysis associated with overall survival with high and low expressions of GFRα2.
Table 1
Relationship between the expression level of GFRα2 and clinical features.
Variable Total GFRα2
expression level
P-value
Low High
Gender 0.107
Male 35 5 30
Female 23 8 15
Tumor size 0.004*
<3 24 10 14
≥3 34 3 31
Perineural invasion 0.031*
Negative 16 7 9
Positive 42 6 36
Lymph node metastasis 0.749
Negative 23 6 17
Positive 35 7 28
TNM stage 0.212
I, II 30 9 21
III, IV 28 4 24
* Signiﬁcant difference (p<0.05).
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peri-tumor tissues (Fig. 4A). Higher expression of Mir-17-5p also
showed a positive correlation with the expression of GFRα2 and is
associated with poorer prognosis as GFRα2 did (Fig. 4B, C and
Table 2).
GFRα2/mir-17-5p/PTEN was correlated with chemoresistance in
PDAC
In order to study the connection between GFRα2 and
chemoresistance, we used gemcitabine (GEM, Selleckchem), the ﬁrst-
line chemotherapeutics in PDAC therapy, as an apoptotic inducer.
50 μM GEM was added in the culture medium for 48 h and ﬂow
cytometry (Annexin-V/PI) was used to detect the apoptotic and dead
rate. Compared with the control group, GFRα2 could signiﬁcantly
inhibit the apoptotic rate (p < 0.05). Next, we usedMir-17-5pmimics
and inhibitor to treat the GFRα2 OE group; we found that Mir-17-5p
could enhance the chemoresistance to GEM, while the cancer cells
could become sensitive to GEM after inhibiting the Mir-17-5p (com-
pared with the control group, p < 0.05). If we over-expressed the
level of PTEN (adenovirus, Ad) before treating with Mir-17-5p
mimics, the apoptotic rate will become higher (p < 0.05) (Fig. 5A–C).
These results demonstrated that GFRα2 could enhance the chemo-
resistance through inhibiting PTEN via up-regulating the Mir-17-
5p level. The mechanism can be described in Fig. 5D.
Discussion
Chemoresistance and fast growth rate are the main reasons for
patients of PDAC suffering from short overall survival time [24], es-
pecially for those with advanced carcinoma. This is a multistep
process that involves complicated factors, and the activation of on-
cogenes and loss of tumor suppressors are thought to act key steps
Fig. 2. GFRα2 enhances cancer cell growth in vitro and in vivo. (A) Validation of the effect of over-expression of GFRα2 in PanC-1 and Mia Paca-2. (B) Colony formation
assay and statistical results in two control cells and stable transfected ones (3 replicates). (C) Proliferation ability test by cell counting kit of two control cells and stable
ones (3 replicates). (D) Functional test of GFRα2 in vivo (Up: GFRα2 OE; Down: Control). (E) Validation of the effect of knock-down of GFRα2 in PanC-1 and Mia Paca-2. (F)
Colony formation assay and statistic results in two control cells and stable ones (3 replicates). (G) Proliferation ability test by cell counting kit of two control cells and stable
ones (3 replicates). (H) Changes of the PTEN expression level between control and GFRα2 over-expression cells by qRT-PCR (3 replicates).
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in the progression of PDAC [25–27]. Therefore, it is necessary to study
the underlying mechanisms of tumor growth and chemoresistance.
This study presented a new role of GFRα2 in tumorigenesis and
chemoresistance in pancreatic ductal adenocarcinoma (PDAC). First,
we found that GFRα2 was up-regulated in pancreatic cancer tissues
and was related to prognosis, tumor size and chemoresistance. Next,
over-expression of GFRα2 did promote tumor growth and down-
regulate PTEN expression level at the same time. Third, we found
thatMir-17-5pwas up-regulated after GFRα2 over-expression in pan-
creatic cancer cell lines and its expression pattern also correlated
with chemoresistance. This correlation could also be validated in
patients’ tissues. With the rescued experiments, we found that Mir-
17-5p played an important role in connecting GFRa2 and PTEN.
Lastly, we used gemcitabine (GEM) to treat pancreatic cancer cells
before and after ectopic expression or knock-down of GFRα2 and
Mir-17-5p. It is highly consistent with our hypothesis that GFRα2
and Mir-17-5p could enhance chemoresistance. Taken together, our
results indicated that GFRα2/Mir-17-5p/PTEN axis played an im-
portant role in tumorigenesis and chemoresistance.
Previous studies about GFRα2 mainly focused on its function in
the ﬁeld of neuroscience. GFRα2-RET signaling provided neces-
sary trophic signals for proper soma size and epidermal innervation
in the IB4-binding nonpeptidergic neurons and development cu-
taneous sensory neurons [28,29]. GFRα2 also correlated with nerve
injury or neurotrophic pain in some certain diseases. Although a
few studies have pointed that GFRα2 acted as an oncogene in cancer,
Fig. 3. Mir-17-5p was up-regulated by GFRα2 and directly targeted to PTEN. (A) Changes of the Mir-17-5p expression level between control cells and GFRα2 over-
expression cells (3 replicates). (B) PTEN expression level before and after Mir-17-5p mimics transfection in Mia Paca-2 cells. (C) Binding sites of Mir-17-5p in 3’UTR of PTEN
mRNA and the mutant base on it. (D) Results of luciferase reporter assay of Mir-17-5p with (Mut-) 3’UTR of PTEN. (E) Co-IP results in Mia Paca-2 cells. (F) Basic information
in treatment approaches. (G) PTEN expression level after different treatment approaches.
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and one article reported it was highly related to perineural inva-
sion and abdominal pain in PDAC [10]. However, the underlying
mechanism in PDAC was still largely unknown.
MatureMirRNAs are non-coding RNAmolecules with 21–25 con-
served nucleotides. The small cellular RNAs can regulate the
biological process of target mRNAs by degrading the mRNAs or in-
hibiting their translation [30]. Thus, up-/down-regulation of MirRNAs
has been linked to the progression of many cancers [31,32]. Lines
of evidence have shown that Mir-17-5p, which belongs to the Mir-
17-92 cluster located in 13q31.3, was up-regulated in various types
of cancer and correlated with cell cycle, apoptosis and prolifera-
tion. Although some studies have already indicated that it acted a
role in chemoresistance in ovarian cancer and targeted PTEN, the
speciﬁc way of Mir-17-5p activation and its role in PDAC are still
unknown [16,20]. Recently, a study based on bioinformatic analy-
sis with hepatitis C virus (HCV) showed that Mir-17-3p (a mature
type of Mir-17) could bind to the 5′UTR region of GFRα2, promot-
ing translational enhancement instead of repression [23]. Although
we could not verify this ﬁnding in pancreatic cancer cells (data not
shown), it inspired us to detect whether there was a regulatory cor-
relation between GFRα2 andMir-17 (including its twomature types:
Mir-17-5p/3p). Although the correlation and the function between
Mir-17-5p and PTEN have been reported in various cancers, its reg-
ulation and activation pathway have not been studied, especially
in PDAC.
In our study, we found a new way of GFRα2 to regulate PTEN ex-
pression and it is effective to inhibit the GFRα2/Mir-17-5p/PTEN axis
in terms of tumor growth and chemoresistance. However, sincemost
of the ﬁndings were obtained from cells and animal tests, it is still
unknown whether inhibiting GFRα2 and Mir-17-5p could inﬂu-
ence other normal functions in vivo, and how to induce the Mir-
17-5p inhibitor into the living body is also a problem that needs
further investigation in the future.
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Fig. 4. Mir-17-5p expression level in paired PDAC samples and its correlation with GFRα2 and prognosis. (A) qRT-PCR based detection of Mir-17-5p expression level in paired
PDAC tissues (2−Δct was used to calculate the expression level, 3 replicates). (B) Statistical correlation between GFRα2 and Mir-17-5p level in paired PDAC samples. (C) Kaplan–
Meier analysis associated with overall survival with high and low expressions of Mir-17-5p.
Table 2
Relationship between the expression level of Mir-17-5p and clinical features.
Variable Total Mir-17-5p
expression level
P-value
Low High
Gender 0.271
Male 35 10 25
Female 23 10 13
Tumor size 0.002*
<3 24 14 10
≥3 34 6 28
Perineural invasion 0.373
Negative 16 7 9
Positive 42 13 29
Lymph node metastasis <0.001*
Negative 23 15 8
Positive 35 5 30
TNM stage
I, II 30 16 14 0.002*
III, IV 28 4 24
* Signiﬁcant difference (p<0.05).
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